Review
Copyright ©The Author(s) 2018.
World J Gastroenterol. Aug 28, 2018; 24(32): 3567-3582
Published online Aug 28, 2018. doi: 10.3748/wjg.v24.i32.3567
Table 2 Biologic agents which have demonstrated efficacy in inflammatory bowel diseases and rheumatology
Mechanism of actionUCCD2FistulizationAnkylosing SpondylitisPsoriasis
Anti-TNF
1Infliximab[20,22,51,119]Chimeric monoclonal antibodyxxxxx
Adalimumab[26,28,54,120,121]Fully human monoclonal antibodyxxxxx
Certolizumab[31,122,123]Pegylated humanized monoclonal antibody Fab' fragmentx+/-xx
Golimumab[57,122,124]Fully human monoclonal antibodyxxx
Anti-integrin
4Natalizumab[39]Chimeric monoclonal antibody against α4 integrinx
3Vedolizumab[46,96]Chimeric monoclonal antibody against α4β7 integrinxx+/-
Ustekinumab[50,125,126]Fully human monoclonal antibody against P40 sub-unit of IL-12 and IL-23x+/-xx